Cargando…
A Fast and Sensitive Luciferase-based Assay for Antibody Engineering and Design of Chimeric Antigen Receptors
Success of immunotherapeutic approaches using genetically engineered antibodies and T cells modified with chimeric antigen receptors (CARs) depends, among other things, on the selection of antigen binding domains with desirable expression and binding characteristics. We developed a luciferase-based...
Autores principales: | Natarajan, Venkatesh, Gopalakrishnan, Ramakrishnan, Matta, Hittu, Choi, Sunju, Gong, Songjie, Jeronimo, Alberto, Keerthipati, Pooja Smruthi, Morales, Anthony, Venkatesh, Harishwar, Chaudhary, Preet M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012821/ https://www.ncbi.nlm.nih.gov/pubmed/32047180 http://dx.doi.org/10.1038/s41598-020-59099-9 |
Ejemplares similares
-
A novel thermostable beetle luciferase based cytotoxicity assay
por: Choi, Sunju, et al.
Publicado: (2021) -
A novel luciferase-based assay for the detection of Chimeric Antigen Receptors
por: Gopalakrishnan, Ramakrishnan, et al.
Publicado: (2019) -
Development and characterization of a novel luciferase based cytotoxicity assay
por: Matta, Hittu, et al.
Publicado: (2018) -
Narciclasine, an isocarbostyril alkaloid, has preferential activity against primary effusion lymphoma
por: Gopalakrishnan, Ramakrishnan, et al.
Publicado: (2020) -
Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors
por: Gopalakrishnan, Ramakrishnan, et al.
Publicado: (2015)